Charlie Kim

Cooley LLP

+ Follow Contact

Latest Posts › Special Purpose Acquisition Companies (SPACs)

Share:

Cooley’s 2022 Life Sciences M&A Year in Review

Although 2022 saw a general decline in M&A activity in the life sciences industry compared to 2021’s frenetic pace (when deal volume was up 52% from 2020), life sciences deal flow in 2022 on balance remained strong despite...more

1/26/2023 / Acquisitions , Federal Trade Commission (FTC) , Initial Public Offering (IPO) , Life Sciences , Mergers , Pharmaceutical Industry , PIPEs , Popular , Special Purpose Acquisition Companies (SPACs)

2021 Update: 10 Key Considerations for Going Public with a SPAC

It is a reasonable extrapolation – and we are nothing at Cooley if not wildly reasonable – that, since the beginning of time, more operating companies are considering going public through a merger with a SPAC (Special Purpose...more

11/8/2021 / Initial Public Offering (IPO) , Merger Agreements , Mergers , Private Investment in Public Equity (PIPEs) , Publicly-Traded Companies , Securities and Exchange Commission (SEC) , Shareholders , Special Purpose Acquisition Companies (SPACs)

Blog: 10 Key Considerations for Going Public with a SPAC

It is a reasonable extrapolation – and we are nothing at Cooley if not wildly reasonable – that more operating companies are considering going public through a merger with a SPAC (commonly referred to as a backdoor IPO) since...more

8/3/2020 / Initial Public Offering (IPO) , Mergers , Private Investment in Public Equity (PIPEs) , Securities and Exchange Commission (SEC) , Shareholders , Special Purpose Acquisition Companies (SPACs)

3 Results

View per page

Page: of 1